|Day Low/High||86.91 / 88.20|
|52 Wk Low/High||69.18 / 99.84|
The move was helped by the TLRY's deals with AB InBev for beverages and Novartis for medical applications.
If we can advance without China then who the heck knows where we can go with it.
Medicine is a slow business and I view Gilead Sciences as a hold for now.
CBD could make coffee an around the clock craze.
One of pharma's biggest CEO's talks M&A action on the exchange.
Canopy Growth's smoking engine won't necessarily ensure smooth sailing for Constellation.
The stock's performance has been impressive in the past three months.
We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.
I'd be most interested in buying this name after a cap raise which I expect in the first quarter of 2019.
Pot stock partnerships are a gateway to gains for cannabis investors.
Tilray will have a lot to tackle this evening.
It's time for the central bank to show the same level of concern for their misplaced aggression.
Tesla will pay $20 million as part of the settlement with Elon Musk paying another $20 million.
Let's check out the latest charts and indicators for some technical guidance.
The company is losing sales aggressively as it fails to create any business substantial enough to make up for the shrinking sales in its Hepatitis C drugs.
Here are two I think will bounce back before the end of the year.
These names are showing bullish or bearish reversal patterns over the past week.
Adamis Pharmaceuticals and Pieris Pharmaceuticals are names to watch.
The drugmaker may have made a low, but the charts indicate we are a long way from a bottom.
Happy Friday! These are the stories you must know ahead of the opening bell.
For my portfolio, you can't beat this SBUX competitor -- and for a cup of coffee.
Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.
Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.
Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.
A look at possible second-quarter M&A activity in the biotech sector.
Two failed bounces this year have made it tougher for stocks to build strong sustained momentum.
U.S. stock futures rise Monday following indications that Donald Trump was softening his approach toward China; Deutsche Bank ousts CEO John Cryan; Novartis buys AveXis; Facebook to notify users whose data may have been shared with Cambridge Analytica.
With Wall Street responding to one of the strongest rallies in years, here's what you need to know premarket Tuesday.